Jove
Visualize
Contact Us

Related Experiment Videos

Variagenics, inc.

Ann E Ferentz1, Joseph S Mohr

  • 1Variagenics, Inc., 60 Hampshire Street Cambridge MA 02139, USA. aferentz@variagenics.com

Pharmacogenomics
|September 12, 2002
PubMed
Summary
This summary is machine-generated.

Variagenics identifies genetic markers to predict cancer therapy response, aiming to personalize patient care. Analyzing multiple genetic variations enhances diagnostic development for optimized cancer treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model for the structure of the Escherichia coli SOS-regulated UmuD2 protein.

DNA repair·2003
Same author

Integrating pharmacogenomics into drug development.

Pharmacogenomics·2002
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Genomics and Personalized Medicine
  • Molecular Diagnostics
  • Cancer Therapeutics

Background:

  • Optimizing patient care in cancer therapy requires understanding individual responses to treatments.
  • Genetic variations play a crucial role in determining drug efficacy and toxicity.
  • Current diagnostic methods may not fully capture the complexity of genetic influences on treatment outcomes.

Purpose of the Study:

  • To develop molecular diagnostic tests for predicting patient response to cancer therapies.
  • To identify significant genetic markers associated with therapeutic drug response.
  • To enhance the precision of cancer treatment selection through personalized diagnostics.

Main Methods:

  • Analysis of genetic variations in both normal and tumor cells.

Related Experiment Videos

  • Examination of single nucleotide polymorphisms (SNPs), haplotypes, and loss of heterozygosity.
  • Assessment of gene expression levels to identify relevant markers.
  • Utilizing biopharmaceutical collaborations and internal research for marker discovery.

    • Main Results:

    • Identification of specific genetic markers linked to cancer drug response.
    • Development of proprietary diagnostic platforms based on identified genetic variations.
    • Increased likelihood of finding significant associations between genetic profiles and treatment outcomes.

    Conclusions:

    • Variagenics' approach of analyzing multiple genetic variations improves the accuracy of diagnostic development.
    • The identified genetic markers have the potential to optimize patient care by guiding cancer therapy selection.
    • Continued research and collaborations are key to advancing personalized cancer diagnostics and treatment.